MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury

Zhengnan Zhang, Suyun Wang, Liping Zhu, Yang Bian, Jing Zhao

Open source

DOI
10.1177/14791641261454501
Published
2026-07
Container
Diabetes & Vascular Disease Research
Publisher
SAGE Publications
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/14791641261454501,
  title = {MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury},
  author = {Zhengnan Zhang and Suyun Wang and Liping Zhu and Yang Bian and Jing Zhao},
  year = {2026},
  journal = {Diabetes \& Vascular Disease Research},
  doi = {10.1177/14791641261454501},
  url = {https://doi.org/10.1177/14791641261454501}
}

RIS

TY  - JOUR
TI  - MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury
AU  - Zhengnan Zhang
AU  - Suyun Wang
AU  - Liping Zhu
AU  - Yang Bian
AU  - Jing Zhao
PY  - 2026
JO  - Diabetes & Vascular Disease Research
DO  - 10.1177/14791641261454501
UR  - https://doi.org/10.1177/14791641261454501
ER  - 

APA

Zhang, Z., Wang, S., Zhu, L., Bian, Y., & Zhao, J. (2026). MiR-143-3p serves as a novel biomarker for diabetic cardiomyopathy and is involved in regulating high glucose-induced cardiomyocyte injury. Diabetes & Vascular Disease Research. https://doi.org/10.1177/14791641261454501

Source records